United Therapeutics Stock Forecast, Price & News

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

Is United Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" United Therapeutics stock.
View analyst ratings for United Therapeutics or view top-rated stocks.

How has United Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

United Therapeutics' stock was trading at $93.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, UTHR stock has increased by 106.0% and is now trading at $193.64.
View which stocks have been most impacted by COVID-19.

Are investors shorting United Therapeutics?

United Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,880,000 shares, a drop of 21.3% from the October 31st total of 2,390,000 shares. Based on an average trading volume of 368,100 shares, the short-interest ratio is currently 5.1 days. Currently, 4.3% of the shares of the company are sold short.
View United Therapeutics' Short Interest.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for United Therapeutics.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) posted its earnings results on Wednesday, November, 3rd. The biotechnology company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.37 by $0.05. The biotechnology company earned $444.70 million during the quarter, compared to the consensus estimate of $421.45 million. United Therapeutics had a trailing twelve-month return on equity of 12.93% and a net margin of 27.94%. The firm's quarterly revenue was up 17.0% compared to the same quarter last year. During the same period in the previous year, the company earned $3.84 earnings per share.
View United Therapeutics' earnings history.

What price target have analysts set for UTHR?

8 Wall Street analysts have issued 12 month price targets for United Therapeutics' shares. Their forecasts range from $196.00 to $275.00. On average, they anticipate United Therapeutics' share price to reach $224.38 in the next year. This suggests a possible upside of 15.9% from the stock's current price.
View analysts' price targets for United Therapeutics or view top-rated stocks among Wall Street analysts.

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the following people:

• Martine A. Rothblatt, Chairman & Chief Executive Officer
• Michael Ian Benkowitz, President & Chief Operating Officer
• James Christopher Edgemond, Chief Financial Officer & Treasurer
• Paul A. Mahon, Secretary, Executive VP & General Counsel
• Dewey Steadman, Head-Investor Relations

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics CEO Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among United Therapeutics' employees.

Who are some of United Therapeutics' key competitors?

Some companies that are related to United Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Incyte (INCY), Exact Sciences (EXAS), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of UTHR's competitors.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), (CELG), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.56%), Renaissance Technologies LLC (6.72%), Bank of New York Mellon Corp (1.88%), Deutsche Bank AG (1.88%), Fuller & Thaler Asset Management Inc. (1.56%) and Geode Capital Management LLC (1.55%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Paul A Mahon, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends for United Therapeutics.

Which major investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Assenagon Asset Management S.A., Invesco Ltd., Thompson Siegel & Walmsley LLC, Great Point Partners LLC, Martingale Asset Management L P, Renaissance Technologies LLC, and Brahman Capital Corp.. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Paul A Mahon, and Raymond Dwek.
View insider buying and selling activity for United Therapeutics or view top insider-selling stocks.

Which major investors are buying United Therapeutics stock?

UTHR stock was purchased by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Epoch Investment Partners Inc., Two Sigma Advisers LP, Bank of Nova Scotia, Two Sigma Investments LP, Bank of New York Mellon Corp, Arrowstreet Capital Limited Partnership, and Goldman Sachs Group Inc..
View insider buying and selling activity for United Therapeutics or or view top insider-buying stocks.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $193.64.

How much money does United Therapeutics make?

United Therapeutics has a market capitalization of $8.72 billion and generates $1.48 billion in revenue each year. The biotechnology company earns $514.80 million in net income (profit) each year or $9.87 on an earnings per share basis.

How many employees does United Therapeutics have?

United Therapeutics employs 950 workers across the globe.

When was United Therapeutics founded?

United Therapeutics was founded in 1996.

What is United Therapeutics' official website?

The official website for United Therapeutics is www.unither.com.

Where are United Therapeutics' headquarters?

United Therapeutics is headquartered at 1040 SPRING ST, SILVER SPRING MD, 20910.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at (301) 608-9292, via email at [email protected], or via fax at 301-608-9291.